Galmed Pharmaceuticals (GLMD) Share-based Compensation (2013 - 2025)
Galmed Pharmaceuticals (GLMD) recorded quarterly Share-based Compensation of $240000.0 in Q4 2025, up 128.57% quarter-over-quarter from $105000.0 in Q3 2025, and up 106.9% on a YoY basis from $116000.0 in Q4 2024.
Galmed Pharmaceuticals (GLMD) Share-based Compensation (2013 - 2025) Analysis & Trends
Galmed Pharmaceuticals' Share-based Compensation history runs 13 years deep, the most recent figure standing at $240000.0 for Q4 2025.
- In Q4 2025, Share-based Compensation rose 106.9% year-over-year to $240000.0; the TTM figure through Dec 2025 stood at $546000.0 (up 2.82% YoY), while the FY2025 annual figure was $546000.0, up 2.82% from the prior year.
- Share-based Compensation was $240000.0 for Q4 2025 at Galmed Pharmaceuticals, up from $105000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $574000.0 in Q3 2021 to a low of $100000.0 in Q2 2025.
- Historically, Share-based Compensation has averaged $257550.0 across 5 years, with a median of $203000.0 in 2022.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation sank 63.24% in 2022, then soared 106.9% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $369000.0 in 2021, then slumped by 50.68% to $182000.0 in 2022, then rose by 7.14% to $195000.0 in 2023, then slumped by 40.51% to $116000.0 in 2024, then jumped by 106.9% to $240000.0 in 2025.
- The last three Share-based Compensation figures came in at $240000.0 (Q4 2025), $105000.0 (Q3 2025), and $100000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Galmed Pharmaceuticals | 2.48 Mn | -1.63 Mn | - | 240,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 240,000.00 |
| Dec 31, 2025 | 240,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Sep 30, 2025 | 105,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Mar 31, 2025 | 101,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Jun 30, 2024 | 130,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Mar 31, 2024 | 153,000.00 |
| Dec 31, 2023 | 195,000.00 |
| Dec 31, 2023 | 195,000.00 |
| Sep 30, 2023 | 226,000.00 |
| Sep 30, 2023 | 226,000.00 |